{"id":"divalproex-dv","safety":{"commonSideEffects":[{"rate":"25-50%","effect":"Tremor"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"15-30%","effect":"Sedation/somnolence"},{"rate":"10-25%","effect":"Weight gain"},{"rate":"5-15%","effect":"Alopecia (hair loss)"},{"rate":"<1-2%","effect":"Hepatotoxicity"},{"rate":"<1%","effect":"Pancreatitis"},{"rate":"1-5%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Divalproex is a compound of sodium valproate and valproic acid that works through multiple mechanisms: it inhibits histone deacetylase enzymes (affecting gene expression), increases GABA synthesis and reduces GABA catabolism (enhancing inhibitory neurotransmission), and may modulate sodium and calcium channels. These combined effects produce anticonvulsant, mood-stabilizing, and neuroprotective properties.","oneSentence":"Divalproex inhibits histone deacetylase and enhances GABA neurotransmission, leading to increased inhibitory signaling in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:46.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy and seizure disorders"},{"name":"Bipolar disorder (acute mania)"},{"name":"Migraine prophylaxis"}]},"trialDetails":[{"nctId":"NCT01588457","phase":"PHASE4","title":"Sequential Multiple Assignment Treatment for Bipolar Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-06","conditions":"Bipolar I Disorder, Bipolar II Disorder","enrollment":112},{"nctId":"NCT00254488","phase":"PHASE4","title":"Treatment of Bipolar Mania in Older Adults","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2005-11","conditions":"Bipolar Disorder, Mania","enrollment":224}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Valproate"],"phase":"marketed","status":"active","brandName":"Divalproex (DV)","genericName":"Divalproex (DV)","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Divalproex inhibits histone deacetylase and enhances GABA neurotransmission, leading to increased inhibitory signaling in the central nervous system. Used for Epilepsy and seizure disorders, Bipolar disorder (acute mania), Migraine prophylaxis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}